文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

右美托咪定在脓毒症患者中的应用:随机对照试验的系统评价与荟萃分析

Use of dexmedetomidine in patients with sepsis: a systematic review and meta-analysis of randomized-controlled trials.
PubMed 文献 · Ann Intensive Care · 2022-08-27
一句话结论在成人脓毒症患者中,与苯二氮䓬类相比右美托咪定可降低死亡率(RR 0.83),但与丙泊酚相比无此获益,且可能增加心律失常发生率。

该系统评价与荟萃分析纳入19项随机对照试验共1929例成人脓毒症患者,比较右美托咪定与其他镇静剂。结果显示右美托咪定降低全因死亡率(RR 0.83;95%CI 0.69~0.99)及24小时白介素6和肿瘤坏死因子α水平,但试验序贯分析提示信息量未达所需。总不良事件风险相似(RR 1.27;95%CI 0.69~2.36),心律失常风险有升高趋势(RR 1.43;95%CI 0.59~3.51)。ICU住院时间、机械通气时长、谵妄发生率及24小时丙氨酸氨基转移酶和肌酐水平未见显著降低。作者认为右美托咪定较苯二氮䓬类可降低死亡率,但较丙泊酚无此优势,未来需RCT确定最受益人群和最佳剂量方案。

要点

  • 与苯二氮䓬类相比,右美托咪定可降低成人脓毒症患者全因死亡率(RR 0.83;95%CI 0.69~0.99),但与丙泊酚相比无此获益。
  • 右美托咪定较其他镇静剂降低24小时白介素6(SMD -2.15;95%CI -3.25~-1.05)和肿瘤坏死因子α(SMD -1.07;95%CI -1.92~-0.22)水平。
  • 总不良事件风险与其它镇静剂相似(RR 1.27;95%CI 0.69~2.36),但心律失常风险有升高趋势(RR 1.43;95%CI 0.59~3.51)。
  • ICU住院时间、机械通气时长、谵妄发生率及24小时丙氨酸氨基转移酶和肌酐水平未见显著降低。
  • 试验序贯分析提示信息量未达所需,作者认为未来需RCT确定最受益的脓毒症人群和最佳剂量方案。

适用人群与场景

  • 成人脓毒症患者,纳入比较右美托咪定与其他镇静剂的随机对照试验。

研究设计与关键结果

  • 系统评价与荟萃分析纳入19项随机对照试验,共1929例成人脓毒症患者,比较右美托咪定与其他镇静剂。
  • 主要终点:右美托咪定降低全因死亡率(RR 0.83;95%CI 0.69~0.99)。
  • 右美托咪定降低24小时白介素6水平(SMD -2.15;95%CI -3.25~-1.05)和肿瘤坏死因子α水平(SMD -1.07;95%CI -1.92~-0.22)。
  • 总不良事件风险相似(RR 1.27;95%CI 0.69~2.36),但右美托咪定增加心律失常风险(RR 1.43;95%CI 0.59~3.51)。
  • ICU住院时间(SMD -0.22;95%CI -0.85~-0.41)、机械通气时长(SMD 0.12;95%CI -1.10~1.35)、谵妄发生率(RR 0.98;95%CI 0.72~1.33)及24小时丙氨酸氨基转移酶和肌酐水平未见显著降低。
  • 试验序贯分析显示信息量未达所需。

证据类型、等级与局限

  • 证据类型:随机对照试验的系统评价与荟萃分析。
  • 局限:试验序贯分析显示信息量未达所需;作者指出未来需RCT确定最受益的脓毒症人群和最佳剂量方案。

对床旁实践的改变

  • 作者认为,在脓毒症患者中右美托咪定较苯二氮䓬类可显著降低死亡率,但较丙泊酚无此获益。
  • 作者认为,右美托咪定较其他镇静剂可显著降低脓毒症患者的炎症反应。
  • 作者认为,右美托咪定可能导致心律失常发生率增加,但总不良事件发生率无显著差异。
  • 作者认为,未来需RCT确定最受益的脓毒症人群和最佳剂量方案。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Dexmedetomidine is widely used in patients with sepsis. However, its effect on septic patients remains controversial. The objective of this study was to summarize all randomized controlled trials (RCTs) examining dexmedetomidine use in sepsis patients.

METHODS: This systematic review and meta-analysis included RCTs comparing dexmedetomidine with other sedatives in adult sepsis patients. We generated pooled relative risks (RRs) and standardized mean differences and performed trial sequential analysis and a cumulative meta-analysis. The primary outcome was mortality, and the secondary outcomes were the length of the intensive care unit stay, duration of mechanical ventilation, number of ventilation-free days, incidence of total adverse event, incidence of delirium, and levels of interleukin 6, tumor necrosis factor alpha, and alanine aminotransferase.

RESULTS: We included 19 RCTs that enrolled 1929 patients. Compared with other sedatives, dexmedetomidine decreased the all-cause mortality (RR 0.83; 95% confidence interval [CI] [0.69, 0.99]) and inflammatory response (interleukin 6 and tumor necrosis factor alpha levels at 24 h: standardized mean difference (SMD) - 2.15; 95% CI [- 3.25, - 1.05] and SMD - 1.07, 95% CI [- 1.92, - 0.22], respectively). Trial sequential analysis showed that it is not up to required information size. The overall risk adverse events was similar between dexmedetomidine and the other sedatives (RR 1.27, 95% CI [0.69, 2.36]), but dexmedetomidine increased the risk of arrhythmias (RR 1.43, 95% CI [0.59, 3.51]). Length of intensive care unit stay (SMD - 0.22; 95% CI [- 0.85, - 0.41]), duration of mechanical ventilation (SMD 0.12; 95% CI [- 1.10, 1.35]), incidence of delirium (RR 0.98; 95% CI [0.72, 1.33]), and levels of alanine aminotransferase and creatinine at 24 h were not significantly reduced.

CONCLUSIONS: Dexmedetomidine in sepsis patients could significantly reduce mortality compared with benzodiazepines but not with propofol. In addition, dexmedetomidine can significantly decrease inflammatory response in patients with sepsis compared with other sedatives. Dexmedetomidine might lead to an increased incidence of arrhythmias, but its safety profile did not show significant differences in the incidence of total adverse events. Future RCTs are needed to determine the sepsis patient population that would benefit most from dexmedetomidine and its optimal dosing regimen.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Zhang T, Mei Q, Dai S, et al. Use of dexmedetomidine in patients with sepsis: a systematic review and meta-analysis of randomized-controlled trials. Ann Intensive Care. 2022. PMID: 36029410. doi:10.1186/s13613-022-01052-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。